Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents

  1. Iborra, M.
  2. Beltrán, B.
  3. Maroto, N.
  4. Navarro-Cortés, P.
  5. Boscá-Watts, M.
  6. Ferrer-Bradley, I.
  7. García-Morales, N.
  8. Sáez-González, E.
  9. Hinojosa, J.
  10. Mínguez, M.
  11. Nos, P.
Journal:
Gastroenterologia y Hepatologia

ISSN: 1578-9519 0210-5705

Year of publication: 2018

Volume: 41

Issue: 9

Pages: 535-543

Type: Article

DOI: 10.1016/J.GASTROHEP.2018.06.001 GOOGLE SCHOLAR